Fluticasone Propionate in Inflammatory Bowel Disease
Although effective for both acute and often long term treatment of inflammatory bowel disease, systemically absorbed corticosteroids have a high incidence of side effects. This article briefly reviews the pharmacokinetics of corticosteroids and the strategics available for reducing systemic side eff...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1990-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1990/769365 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Although effective for both acute and often long term treatment
of inflammatory bowel disease, systemically absorbed corticosteroids have a high
incidence of side effects. This article briefly reviews the pharmacokinetics of
corticosteroids and the strategics available for reducing systemic side effects. In
particular, fluitcasone propionate is a fluorinated glucocorticoid, in which systemic
side effects are absent or minimal due to its relatively low absorption and
rapid first pass metabolism In an open trial in 12 patients with mild and
moderately active Crohn's disease, administration of 20 mg fluitcasone
propionate orally was associated with a significant fall in the Crohn's disease
activity index and improvement in other parameters of inflammation, without
change in either plasma cortisol levels or responsiveness to adrenocorticotropic
hormone, suggesting that this drug is a promising therapy for Crohn's disease
meriting evaluation against conventional corticosteroids. |
|---|---|
| ISSN: | 0835-7900 |